Completed PHASE3 INTERVENTIONAL NCT00098007

A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients

Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in Addition to Certican and Steroids in de Novo Heart Transplant Recipients

Sponsor: Novartis Pharmaceuticals

Conditions Heart Transplantation

Interventions Everolimus (Certican)

Updated 7 times since 2017 Last updated: Feb 20, 2017 Started: Aug 9, 2004 Primary completion: Jan 8, 2007 Completion: Jan 8, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Heart Transplantation and is currently completed. Novartis Pharmaceuticals leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — May 2017 [monthly]

Completed PHASE3

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Barcelona, Spain , Belo Horizonte, Brazil , Birmingham, United States , Chermside, Australia , Darlinghurst, Australia , Durham, United States , Hanover, Germany , Houston, United States , Innsbruck, Austria and 16 more locations